Take part in our research and tell us what you would like to learn about access to medicines.
We’re proud to support Clinigen’s mission to get hard-to-reach medicines to the people who need them most. But why are some medicines hard to reach? Keep reading to find out.
In partnership with Clinigen, we’re co-creating a new training programme for patient organisations to learn about early access to medicines. But what makes a medicine hard to reach?
A medicine will be tested in patient populations in research studies and pass key safety and effectiveness checkpoints to receive approval from the regulatory body of the country in which it is to be prescribed. This process is called “licensing”.
Until a medicine has been approved in this way, it’s called an “unlicensed medicine”.
Accessing unlicensed medicines
You might wonder what an unlicensed medicine is? How do medicines become licensed for use? There are many medicines that are licensed in some countries and not in others.
This means that some patients have access to a medicine they need whilst others don’t, purely because of the country they live in. We want to provide training on the way medicines are developed right through to routes to access medicines.
Navigating early medicines access
Thankfully, there are ways to navigate early medicines access for the patients who need it the most, but they require in-depth knowledge and understanding. That’s where our new training programme comes in.
We want to equip patient organisations with the skills and knowledge to advocate for early medicines access through a free one-day training programme that covers everything you need to know to access unlicensed medicines.
How can you help?
To make the training as useful and relevant as possible, we’ve created a survey to find out more about the topics you would like to learn. It should take around 5-10 minutes to complete. Have your say today by clicking here: navigateresearch.co.uk